Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. N-MOmentum is a prospecti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis Jg. 27; H. 13; S. 2052
Hauptverfasser:	Cree, Bruce Ac, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Williams, Ian M, Drappa, Jorn, She, Dewei, Cimbora, Daniel, Rees, William, Ratchford, John N, Katz, Eliezer
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.11.2021
Schlagworte:	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Aquaporin 4 Humans Neuromyelitis Optica - drug therapy Prospective Studies clinical trial patient demographics Attack risk neuromyelitis optica spectrum disorder neuromyelitis optica sensitivity analyses Devic’s disease inebilizumab
ISSN:	1477-0970, 1477-0970
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!